Concorde Asset Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$584K Sell
635
-255
-29% -$259K 0.29% 78
2025
Q4
$956K Buy
890
+9
+1% +$8.61K 0.38% 49
2025
Q3
$717K Buy
+881
New +$656K 0.3% 69
2025
Q1
$765K Buy
1,015
+115
+13% +$95.7K 0.41% 31
2024
Q4
$695K Sell
900
-206
-19% -$171K 0.36% 46
2024
Q3
$980K Sell
1,106
-4
-0.4% -$3.6K 0.55% 31
2024
Q2
$1.01M Buy
1,110
+133
+14% +$106K 0.62% 27
2024
Q1
$760K Buy
977
+21
+2% +$14.9K 0.52% 30
2023
Q4
$557K Sell
956
-92
-9% -$53.7K 0.38% 44
2023
Q3
$563K Buy
1,048
+35
+3% +$18K 0.51% 41
2023
Q2
$475K Buy
+1,013
New +$425K 0.44% 44
2023
Q1
Sell
-1,009
Closed -$369K 121
2022
Q4
$369K Sell
1,009
-1
-0.1% -$355 0.33% 73
2022
Q3
$327K Buy
+1,010
New +$320K 0.37% 81
2022
Q2
Sell
-976
Closed -$279K 145
2022
Q1
$279K Buy
+976
New +$251K 0.19% 114
2021
Q4
Sell
-929
Closed -$214K 186
2021
Q3
$214K Buy
929
+45
+5% +$11.1K 0.12% 177
2021
Q2
$203K Buy
+884
New +$178K 0.11% 187
2015
Q3
Sell
-2,926
Closed -$221K 114
2015
Q2
$221K Sell
2,926
-251
-8% -$19.1K 0.28% 89
2015
Q1
$230K Buy
3,177
+160
+5% +$11.4K 0.26% 99
2014
Q4
$207K Buy
+3,017
New +$204K 0.26% 86

Other funds holding LLY

Concorde Asset Management's LLY Position: Q1 2026 in Review

Concorde Asset Management reduced its Eli Lilly (LLY) stake by 29% in Q1 2026, selling an estimated $259K and leaving 635 shares worth $584K. The position accounts for 0.29% of the portfolio, ranked #78.

Concorde Asset Management first reported a position in LLY in Q4 2014 and has held it in 19 quarters since. The position peaked at $1.01M in Q2 2024. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Concorde Asset Management held 635 shares of Eli Lilly worth $584K as of Q1 2026.
  • Concorde Asset Management sold 255 Eli Lilly shares in Q1 2026, an estimated $259K.
  • Eli Lilly made up 0.29% of Concorde Asset Management's portfolio in Q1 2026, its #78 holding.
  • Concorde Asset Management first reported a position in Eli Lilly in Q4 2014 and has held it in 19 quarters since.
  • Concorde Asset Management's Eli Lilly position peaked at $1.01M in Q2 2024.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Concorde Asset Management's 13F filing for Q1 2026, filed 1 Jun 2026.